glp 1 microdosing menopause THE PCCA BLOG Microdosing GLP‑1 in Menopause &

Im just very concerned about how were using these medications as a quick fix for a complex problem, says Dan Cooper

Whilst exact mechanisms remain unclear, a combination of risk factor reduction in improved HbA1c, weight, metabolic profile, as well as direct effects of GLP-1 agonism on coronary endothelial function and improved microvascular perfusion is likely at play

"Now that GLP-1based therapies have been shown to increase the risk of pancreatic inflammation and abnormal cell proliferation, further studies are needed to urgently clarify whether these linkages lead to pancreatic cancer with long-term use." Study co-authors, in addition to Butler and Atkinson, are Alexandra E

FDA registration of the facility does not constitute FDA approval or endorsement of any compounded medication

More states are considering dropping GLP-1 drugs from their Medicaid programs